Cover Image

Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C) in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Yardley, Denise (Author) , Coleman, R. (Author) , Conte, P. (Author) , Cortes, J. (Author) , Brufsky, A. (Author) , Shtivelband, M. (Author) , Young, R. (Author) , Bengala, C. (Author) , Ali, H. (Author) , Eakel, J. (Author) , Schneeweiss, Andreas (Author) , de la Cruz-Merino, L. (Author) , Wilks, S. (Author) , O’Shaughnessy, J. (Author) , Glück, S. (Author) , Li, H. (Author) , Miller, J. (Author) , Barton, D. (Author) , Harbeck, N. (Author)
Format: Article (Journal)
Language:English
Published: 6 June 2018
In: Annals of oncology
Year: 2018, Volume: 29, Issue: 8, Pages: 1763-1770
ISSN:1569-8041
DOI:10.1093/annonc/mdy201
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1093/annonc/mdy201
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0923753419341225
Get full text
Author Notes:D.A. Yardley, R. Coleman, P. Conte, J. Cortes, A. Brufsky, M. Shtivelband, R. Young, C. Bengala, H. Ali, J. Eakel, A. Schneeweiss, L. de la Cruz-Merino, S. Wilks, J. O’Shaughnessy, S. Glück, H. Li, J. Miller, D. Barton & N. Harbeck
Description
Summary:Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C) in patients with mTNBC. - Patients and methods - Patients with pathologically confirmed mTNBC and no prior chemotherapy for metastatic BC received (1 : 1 : 1) nab-P 125mg/m2 plus C AUC 2, nab-P 125mg/m2 plus G 1000mg/m2, or G 1000mg/m2 plus C AUC 2, all on days 1, 8 q3w. Phase II primary end point: investigator-assessed progression-free survival (PFS); secondary end points included overall response rate (ORR), overall survival (OS), percentage of patients initiating cycle 6 with doublet therapy, and safety. - Results - In total, 191 patients were enrolled (nab-P/C, n=64; nab-P/G, n=61; G/C, n=66). PFS was significantly longer with nab-P/C versus nab-P/G [median, 8.3 versus 5.5months; hazard ratio (HR), 0.59 [95% CI, 0.38-0.92]; P=0.02] or G/C (median, 8.3 versus 6.0months; HR, 0.58 [95% CI, 0.37-0.90]; P=0.02). OS was numerically longer with nab-P/C versus nab-P/G (median, 16.8 versus 12.1months; HR, 0.73 [95% CI, 0.47-1.13]; P=0.16) or G/C (median, 16.8 versus 12.6months; HR, 0.80 [95% CI, 0.52-1.22]; P=0.29). ORR was 73%, 39%, and 44%, respectively. In the nab-P/C, nab-P/G, and G/C groups, 64%, 56%, and 50% of patients initiated cycle 6 with a doublet. Grade ≥3 adverse events were mainly hematologic.
Item Description:Im Titel erscheint "nab" klein geschrieben und schräg gestellt
Gesehen am 22.04.2020
Physical Description:Online Resource
ISSN:1569-8041
DOI:10.1093/annonc/mdy201

Similar Items